Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Aligos Therapeutics, Inc. | Director | Common Stock | 183K | $139K | $0.76 | Oct 25, 2023 | Direct |
Adverum Biotechnologies, Inc. | Director | Common Stock | 100K | $135K | $1.35 | Feb 7, 2024 | Direct |
Adverum Biotechnologies, Inc. | Director | Common Stock | 3.33K | $4.5K | $1.35 | Feb 7, 2024 | By Trust |
Aligos Therapeutics, Inc. | Director | Warrant (Right to Buy) | 91.5K | Oct 25, 2023 | Direct | ||
Aligos Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 60K | Jun 27, 2024 | Direct | ||
Adverum Biotechnologies, Inc. | Director | Stock Option (Right to Buy) | 10.5K | Jun 17, 2024 | Direct | ||
DICE Therapeutics, Inc. | Director | Common Stock | 0 | $46.50 | Aug 9, 2023 | By Trust | |
DICE Therapeutics, Inc. | Director | Common Stock | 0 | $46.50 | Aug 9, 2023 | Direct | |
DICE Therapeutics, Inc. | Director | Stock Option (right to buy) | 0 | Aug 9, 2023 | Direct |